Rare blood disorders are complex diseases that affect blood cell production, function or clotting and often have limited therapeutic options. Protheragen is focused on providing customized diagnostic and therapeutic development solutions for these diseases to facilitate disease management.
Given the unique challenges of treating rare blood diseases, Protheragen steadfastly develops a diverse array of molecular modalities tailored to address specific needs. Our team of scientists excels in constructing precise animal models that faithfully replicate key disease features. These models are used for comprehensive preclinical evaluations covering pharmacodynamics (PD), pharmacokinetics (PK) and toxicology studies to accelerate the screening process of drug candidates and facilitate a seamless transition to clinical translation.
Myeloproliferative Disorders (MPDs)
Bone Marrow Failure Syndromes (BMFS)
